Company Description
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States.
The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.
The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018.
Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 20, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Dr. Andrew Cheng M.D., Ph.D. |
Contact Details
Address: 601 Gateway Boulevard, Suite 350 South San Francisco, California 94080 United States | |
| Phone | 650-487-6488 |
| Website | akerotx.com |
Stock Details
| Ticker Symbol | AKRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001744659 |
| CUSIP Number | 00973Y108 |
| ISIN Number | US00973Y1082 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew Cheng M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Executive Vice President, Chief Operating Officer and Secretary |
| Dr. Timothy Rolph | Co-Founder and Chief Scientific Officer |
| William R. White J.D. | Executive Vice President, Chief Financial Officer, Treasurer and Head of Corporate Development |
| Catriona Yale | Executive Vice President and Chief Development Officer |
| Patrick Lamy | Senior Vice President of Commercial Strategy |
| John J. Schembri | Vice President of Finance and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 1, 2024 | 144 | Filing |
| Mar 18, 2024 | 8-K | Current Report |
| Mar 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 6, 2024 | 8-K | Current Report |
| Mar 6, 2024 | 424B5 | Filing |
| Mar 4, 2024 | 144 | Filing |
| Mar 4, 2024 | 144 | Filing |
| Mar 4, 2024 | 424B5 | Filing |
| Mar 4, 2024 | 8-K | Current Report |